Efficient bone marrow irradiation and low uptake by non-haematological organs with an yttrium-90-anti-CD66 antibody prior to haematopoietic stem cell transplantation.

ABSTRACT: We report the results of a Phase I radiation dose escalation study using an yttrium-90 (⁹⁰Y) labelled anti-CD66 monoclonal antibody given with standard conditioning regimen for patients receiving haematopoietic stem cell transplants for myeloid leukaemia or myeloma. The ⁹⁰Y-labelled anti-CD66 was infused prior to standard conditioning. In total, 30 patients entered the trial and 29 received ⁹⁰Y-labelled mAb, at infused radiation activity levels of 5, 10, 25, or 37.5 megaBequerel (MBq)/kg lean body weight. A prerequisite for receiving the ⁹⁰Y-labelled mAb was favourable dosimetry determined by single-photon emission computerised tomography (SPECT) dosimetry following administration of indium-111 (¹¹¹In) anti-CD66. Estimated absorbed rad

SUBMITTER: Orchard K 

PROVIDER: S-EPMC11368815 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature